Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.
Identifieur interne : 000545 ( Ncbi/Merge ); précédent : 000544; suivant : 000546Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.
Auteurs : Hongpeng Jia [États-Unis]Source :
- Shock (Augusta, Ga.) [ 1540-0514 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Humains, Inflammation (immunologie), Inflammation (métabolisme), Maladies pulmonaires (enzymologie), Maladies pulmonaires (immunologie), Maladies pulmonaires (métabolisme), Peptidyl-Dipeptidase A (génétique), Peptidyl-Dipeptidase A (métabolisme), Poumon (immunologie), Poumon (métabolisme), Poumon (virologie).
- MESH :
- enzymologie : Maladies pulmonaires.
- génétique : Peptidyl-Dipeptidase A.
- immunologie : Inflammation, Maladies pulmonaires, Poumon.
- métabolisme : Inflammation, Maladies pulmonaires, Peptidyl-Dipeptidase A, Poumon.
- virologie : Poumon.
- Animaux, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : Peptidyl-Dipeptidase A.
- enzymology : Lung Diseases.
- immunology : Inflammation, Lung, Lung Diseases.
- metabolism : Inflammation, Lung, Lung Diseases, Peptidyl-Dipeptidase A.
- virology : Lung.
- Animals, Humans.
Abstract
In response to infectious and, in some instances, noninfectious insults, the affected tissues/cells of the host undergo inflammation. However, uncontrolled inflammation could be detrimental to the host, resulting in inflammatory disease, such as inflammatory lung disease. Although the etiology of the disease is well defined, the underling pathogenesis is still incompletely understood. The renin-angiotensin system (RAS), one of the primary cardiovascular regulatory systems, has been proposed to be involved in the pathogenesis of inflammatory lung disease. In particular, the RAS has been implicated as advances in the understanding of the multifunctionality of individual components of the system have been made, and by the fact that the RAS acts not only systemically, but also locally in a variety of tissues, including the lung. Angiotensin-converting enzyme 2 (ACE2), a relatively new member of the RAS, has drawn extensive attention since 2003, because of the findings that ACE2 is the receptor for SARS Corona virus and that maintenance of normal ACE2 levels in the lung is beneficial for the host to combat inflammatory lung disease. Nevertheless, the mechanism through which ACE2 plays a role in inflammatory lung disease has not been clearly identified. In an attempt to summarize current literature findings and progress made in uncovering the role of ACE2 in inflammatory lung disease, this review will focus on recent studies examining pulmonary ACE2 biology, its roles in inflammatory lung disease pathogenesis and possible underlying mechanisms. Finally, we will discuss pulmonary ACE2 as a potential therapeutic target for inflammatory lung disease.
DOI: 10.1097/SHK.0000000000000633
PubMed: 27082314
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000626
- to stream PubMed, to step Curation: 000626
- to stream PubMed, to step Checkpoint: 000616
Links to Exploration step
pubmed:27082314Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.</title>
<author><name sortKey="Jia, Hongpeng" sort="Jia, Hongpeng" uniqKey="Jia H" first="Hongpeng" last="Jia">Hongpeng Jia</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27082314</idno>
<idno type="pmid">27082314</idno>
<idno type="doi">10.1097/SHK.0000000000000633</idno>
<idno type="wicri:Area/PubMed/Corpus">000626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000626</idno>
<idno type="wicri:Area/PubMed/Curation">000626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000626</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000616</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000616</idno>
<idno type="wicri:Area/Ncbi/Merge">000545</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.</title>
<author><name sortKey="Jia, Hongpeng" sort="Jia, Hongpeng" uniqKey="Jia H" first="Hongpeng" last="Jia">Hongpeng Jia</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Shock (Augusta, Ga.)</title>
<idno type="eISSN">1540-0514</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Inflammation (immunology)</term>
<term>Inflammation (metabolism)</term>
<term>Lung (immunology)</term>
<term>Lung (metabolism)</term>
<term>Lung (virology)</term>
<term>Lung Diseases (enzymology)</term>
<term>Lung Diseases (immunology)</term>
<term>Lung Diseases (metabolism)</term>
<term>Peptidyl-Dipeptidase A (genetics)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Inflammation (immunologie)</term>
<term>Inflammation (métabolisme)</term>
<term>Maladies pulmonaires (enzymologie)</term>
<term>Maladies pulmonaires (immunologie)</term>
<term>Maladies pulmonaires (métabolisme)</term>
<term>Peptidyl-Dipeptidase A (génétique)</term>
<term>Peptidyl-Dipeptidase A (métabolisme)</term>
<term>Poumon (immunologie)</term>
<term>Poumon (métabolisme)</term>
<term>Poumon (virologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Maladies pulmonaires</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Lung Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Inflammation</term>
<term>Maladies pulmonaires</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Inflammation</term>
<term>Lung</term>
<term>Lung Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Inflammation</term>
<term>Lung</term>
<term>Lung Diseases</term>
<term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Inflammation</term>
<term>Maladies pulmonaires</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In response to infectious and, in some instances, noninfectious insults, the affected tissues/cells of the host undergo inflammation. However, uncontrolled inflammation could be detrimental to the host, resulting in inflammatory disease, such as inflammatory lung disease. Although the etiology of the disease is well defined, the underling pathogenesis is still incompletely understood. The renin-angiotensin system (RAS), one of the primary cardiovascular regulatory systems, has been proposed to be involved in the pathogenesis of inflammatory lung disease. In particular, the RAS has been implicated as advances in the understanding of the multifunctionality of individual components of the system have been made, and by the fact that the RAS acts not only systemically, but also locally in a variety of tissues, including the lung. Angiotensin-converting enzyme 2 (ACE2), a relatively new member of the RAS, has drawn extensive attention since 2003, because of the findings that ACE2 is the receptor for SARS Corona virus and that maintenance of normal ACE2 levels in the lung is beneficial for the host to combat inflammatory lung disease. Nevertheless, the mechanism through which ACE2 plays a role in inflammatory lung disease has not been clearly identified. In an attempt to summarize current literature findings and progress made in uncovering the role of ACE2 in inflammatory lung disease, this review will focus on recent studies examining pulmonary ACE2 biology, its roles in inflammatory lung disease pathogenesis and possible underlying mechanisms. Finally, we will discuss pulmonary ACE2 as a potential therapeutic target for inflammatory lung disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27082314</PMID>
<DateCompleted><Year>2018</Year>
<Month>01</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>03</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>46</Volume>
<Issue>3</Issue>
<PubDate><Year>2016</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>Shock (Augusta, Ga.)</Title>
<ISOAbbreviation>Shock</ISOAbbreviation>
</Journal>
<ArticleTitle>Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease.</ArticleTitle>
<Pagination><MedlinePgn>239-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SHK.0000000000000633</ELocationID>
<Abstract><AbstractText>In response to infectious and, in some instances, noninfectious insults, the affected tissues/cells of the host undergo inflammation. However, uncontrolled inflammation could be detrimental to the host, resulting in inflammatory disease, such as inflammatory lung disease. Although the etiology of the disease is well defined, the underling pathogenesis is still incompletely understood. The renin-angiotensin system (RAS), one of the primary cardiovascular regulatory systems, has been proposed to be involved in the pathogenesis of inflammatory lung disease. In particular, the RAS has been implicated as advances in the understanding of the multifunctionality of individual components of the system have been made, and by the fact that the RAS acts not only systemically, but also locally in a variety of tissues, including the lung. Angiotensin-converting enzyme 2 (ACE2), a relatively new member of the RAS, has drawn extensive attention since 2003, because of the findings that ACE2 is the receptor for SARS Corona virus and that maintenance of normal ACE2 levels in the lung is beneficial for the host to combat inflammatory lung disease. Nevertheless, the mechanism through which ACE2 plays a role in inflammatory lung disease has not been clearly identified. In an attempt to summarize current literature findings and progress made in uncovering the role of ACE2 in inflammatory lung disease, this review will focus on recent studies examining pulmonary ACE2 biology, its roles in inflammatory lung disease pathogenesis and possible underlying mechanisms. Finally, we will discuss pulmonary ACE2 as a potential therapeutic target for inflammatory lung disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jia</LastName>
<ForeName>Hongpeng</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Shock</MedlineTA>
<NlmUniqueID>9421564</NlmUniqueID>
<ISSNLinking>1073-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>1</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27082314</ArticleId>
<ArticleId IdType="doi">10.1097/SHK.0000000000000633</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Jia, Hongpeng" sort="Jia, Hongpeng" uniqKey="Jia H" first="Hongpeng" last="Jia">Hongpeng Jia</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000545 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000545 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:27082314 |texte= Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27082314" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a CovidV1
This area was generated with Dilib version V0.6.33. |